The company teaching blood to clot faster - and betting a nanoparticle can beat the bleed.
Here is a fact that should bother you more than it does. If you are bleeding somewhere you can press on - an arm, a leg - a tourniquet or a bandage buys you time. If you are bleeding somewhere you cannot press on - deep, internal, from a car crash or a surgery or a dose of blood thinner that worked a little too well - the field has, historically, had much less to offer. That second kind, "non-compressible hemorrhage," is a leading cause of preventable death in trauma. Cayuga Biotech, a roughly 11-person company headquartered in New York, is building for exactly that case.
The pitch is elegant in the way good biology usually is. Your platelets already store a molecule called polyphosphate. When you get hurt, they release it, and it acts as a cofactor - a helper - that accelerates the production of thrombin, the enzyme at the center of the clotting cascade. Polyphosphate, in other words, is part of how your body already stops itself from bleeding out. It is not exotic. It is inventory you were born with.
Cayuga's insight was not to invent a new molecule. It was to make a synthetic version, package it onto a silica nanoparticle, and deliver it where the blood is actually escaping. The lead candidate, CAY001, is described as a first-in-class synthetic polyphosphate-silica nanoparticle complex - polyP-SNP, if you like acronyms, which biotech does. It is engineered to remain inert as it circulates and to switch on at the site of a bleed. The clever part is the aim, not just the payload.
This matters because most drugs in the neighborhood work on the other half of the equation. Antifibrinolytics like tranexamic acid slow down how fast a clot breaks apart. Reversal agents undo the effect of a specific anticoagulant. Both are useful. Both are, mechanically, about preserving or protecting a clot. Cayuga is trying to help the clot form faster in the first place. As the company puts it, with the plainness of a slide that has been through many investor meetings: "PolyP enables clot formation; current treatments slow clot breakdown."
If that reframing sounds small, it is worth sitting with, because a lot of hard problems turn out to be someone optimizing the wrong half of an equation. The bleeding that kills people in trauma bays often happens under the worst possible conditions - what emergency physicians call the "lethal triad" of acidosis, hypothermia, and coagulopathy, each one making the others worse. Cayuga says CAY001 is designed for those conditions, the messy edge case, rather than the tidy version that behaves in a lab.
The polyP-SNP complex moves through the bloodstream and stays inert - no clotting where it isn't needed.
At a bleeding site, it concentrates where vascular injury has occurred, mirroring what platelets do naturally.
Polyphosphate acts as a cofactor, normalizing and speeding thrombin production - the hallmark of coagulation.
The natural cascade forms a clot faster, aimed at bleeding that can't be reached with pressure.
"Harnessing the body's innate ability to stop bleeding with first-in-class therapeutics."
Conceptual illustration of mechanism, not a head-to-head efficacy claim.
A synthetic polyphosphate-silica nanoparticle (polyP-SNP) complex for life-threatening, non-compressible hemorrhage from trauma, surgery, and blood thinners. The program the seed and defense funding are pushing into the clinic.
An earlier program aimed at inherited bleeding disorders - hemophilia and other rare coagulation deficiencies - extending the polyphosphate platform beyond acute trauma.
The underlying idea: a natural cofactor stored in platelets that normalizes thrombin production, localizes to bleeding sites, and stays inert elsewhere. One mechanism, several possible indications.
Cayuga is small, but the resume behind the science is dense. In biotech, who is building a thing tells you a lot about whether it will ship.
Invented CAY001. Earned a Materials Chemistry PhD at UC Santa Barbara, where his thesis developed a nanoparticle that delivers an endogenous polymer to injury sites to accelerate coagulation. A Cornell alumnus - the school that sits above Cayuga Lake.
Appointed CEO in 2022. More than 20 years in pharma, including work that helped bring the rare-disease therapy RETHYMIC through BLA approval.
Inventor of ANDEXXA, an approved anticoagulant reversal agent. Two-plus decades in R&D and 40+ patents to his name.
Co-founded the company alongside Kudela, bringing brain-sciences research expertise to the preclinical program.
The seed round - $8 million, announced in 2026 - was led by Wharton Alumni Angels, which put in roughly $5 million. The rest came from a broad syndicate that reads like a tour of the early-stage angel world: Gopher Angels, Mass Medical Angels, New York Ventures, NuFund Venture Group, Purchase Capital, SideCar Ventures, SOSV, TBD Angels, and Walnut Ventures.
The more interesting line item is the $3 million from the Defense Health Agency, awarded through the Medical Technology Enterprise Consortium. It is non-dilutive - the government does not take equity - and it is a tell. Non-compressible hemorrhage is a battlefield problem before it is anything else, and the military has a long, specific interest in stopping bleeding that a medic cannot reach. When the Pentagon's health arm co-signs your mechanism, that is a form of validation money can't quite buy.
Cayuga Biotech's official YouTube channel hosts its talks and explainer content on the science of hemorrhage control.
Cayuga Biotech is a clinical-stage biotech developing first-in-class therapeutics that stop life-threatening bleeding by accelerating the body's own clotting cascade. Its lead candidate, CAY001, is a synthetic polyphosphate-silica nanoparticle (polyP-SNP) designed to work where conventional hemostatic agents fall short - non-compressible hemorrhage from trauma, surgery, blood thinners and inherited bleeding disorders. Founded on research from UC Santa Barbara, the company harnesses polyphosphate, a natural cofactor stored in platelets, to normalize thrombin production and speed clot formation without slowing clot breakdown.
Last updated: